高催乳素血症
医学
催乳素瘤
卡麦角林
内科学
催乳素
内分泌学
赛庚啶
多巴胺激动剂
脑脊液
肢端肥大症
垂体瘤
Pegvisomant公司
闭经
垂体卒中
垂体腺瘤
垂体
垂体疾病
生长激素
溴隐亭
兴奋剂
作者
Ghazal Daftari,R. Waki,Deborah Forst,Pamela S Jones,Nicholas A. Tritos
出处
期刊:Case Reports
[BMJ]
日期:2026-07-01
卷期号:19 (7): e272948-e272948
标识
DOI:10.1136/bcr-2026-272948
摘要
We report a woman in her 50s with a giant co-secreting pituitary macroadenoma producing both prolactin and growth hormone. She presented with headache, proptosis, chemosis and secondary amenorrhoea since her 20s. Workup showed hyperprolactinaemia (251 μg/L; normal ≤23 μg/L). A brain MRI showed a giant mass at the base of the skull. Repeat prolactin assay after serum dilution showed marked hyperprolactinaemia (386 020 μg/L), consistent with a giant prolactin-secreting tumour. Additional tests established the presence of growth hormone excess. She was treated with cabergoline, leading to substantial clinical improvement and progressive decrease in tumour size and prolactin. Additionally, she was initially treated with lanreotide which was ineffective. She was switched to pegvisomant therapy, resulting in insulin-like growth factor I normalisation. This case emphasises the critical importance of recognising the hook effect artefact in patients with large sellar masses. Slow uptitration of dopamine agonist therapy is advisable in patients with large tumours to minimise the risks of cerebrospinal fluid leak, apoplexy and herniation.
科研通智能强力驱动
Strongly Powered by AbleSci AI